$ 1.18
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of IFRX is 4.0 and suggests 242% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
